GSK announces US regulatory submission for fluticasone furoate monotherapy for asthma

GlaxoSmithKline plc (LSE:GSK) today announced the submission of a New Drug Application (NDA) in the US for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF), administered using the ELLIPTA™ dry powder inhaler.
Source: GSK news - Category: Pharmaceuticals Source Type: news